Inflammatory disease Archives

Best in Biotech 15 Mar 2023

10 immunotherapy companies making waves in 2023

Immunotherapy has been widely studied in cancer treatment research, ever since William Coley, who is regarded as the father of immunotherapy, first attempted to leverage the immune system for oncological therapy in 1891. Soon enough, the transformative power of cancer vaccines were observed where tumor-specific antigens triggered antitumor immune responses. Along with these technological advancements, […]

March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 3 Mar 2023

Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor

Laevoroc Immunology, a privately-owned, Swiss oncology development company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for immune checkpoint inhibitor LR 09. LR 09 is a novel metabolic immune checkpoint inhibitor, for the treatment of patients with hematological malignancies who are diagnosed with a relapse after allogeneic stem […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Positive topline data from sepsis trial

Modus Therapeutics AB has published positive top-line data from its phase 1b lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a treatment for sepsis and other conditions with systemic inflammation. In the study, healthy volunteers received LPS to induce a transient systemic inflammation reaction together with […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Certa scleroderma study shows improvement in more than 60% of patients

Certa Therapeutics has announced what it says are ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases. Certa Therapeutics has recently completed a global phase 2, multi-centre, randomized, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, of oral FT011 in patients with scleroderma. […]

February 7, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

FDA clearance for ‘revolutionary’ approach to J-Pouch issue

ExeGi Pharma LLC, which develops live biotherapeutic drugs and probiotics, says the FDA has cleared its Investigational New Drug (IND) application for its biologic drug candidate, EXE-346. The clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis (IPAA or J-Pouch) who experience excessive stool frequency. “Excessive stool frequency […]

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Lupus treatment hope from Japanese miRNA research

A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. They identified two miRNAs that are downregulated in the disease and an uncommon situation that occurs in which multiple miRNAs regulate the same set of genes. Although […]

January 26, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

CytoReason expands deal with Sanofi to look at IBD

CytoReason, which creates computational disease modeling, has announced an expansion of its collaboration with Sanofi. The multi-year collaboration will further fuel Sanofi’s target discovery efforts via CytoReason’s AI platform in the field of inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets. In 2021, Cytoreason announced the initiation of a […]

January 24, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

Anticancer drugs could lead to new sepsis treatment

Researchers at the Instituto Gulbenkian de Ciência (IGC) in Oeiras, Portugal, say because anti-cancer drugs limit inflammation, they could be a potential treatment for sepsis. The study, published in eLife, reveals that the class of drugs used in cancer treatment limit the unrestrained production of inflammatory mediators by the immune system. The discovery positions these […]

January 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Positive Dupixent eosinophilic esophagitis phase 3 results

The New England Journal of Medicine has published results from a positive phase 3 trial showing adults and adolescents treated with Dupixent (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (EoE), which were sustained for up to one year. EoE is a chronic, progressive inflammatory disease that damages the […]

December 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

Apogee Therapeutics raises $169M to tackle immunological and inflammatory disorders

Apogee Therapeutics, LLC, a biotech company advancing novel, potentially best-in-class therapies to address immunological and inflammatory disorders, has announced the closing of a $149 million Series B financing. Proceeds will be used to support Apogee’s plans to advance its lead pipeline program into the clinic in 2023 and expand the leadership, scientific, and clinical teams […]

December 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 6 Dec 2022

Tetra announce significant results from the study of Onternabez combined with Favipiravir

Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir. The combination acts against ARDS (acute respiratory distress syndrome), Sepsis, and Covid-19 through PREPAiRE, an artificial intelligence (AI) powered platform. The platform, the companies say, purposely integrates target identification, validation, lead discovery […]

December 6, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Dec 2022

First subject dosed in inflammation phase I study

Innovent Biologics, Inc. and UNION therapeutics A/S have announced that the first Chinese healthy volunteer has been successfully dosed in the phase I study of orismilast, a potential best-in-class PDE4 inhibitor in global clinical phase II stage. This study is a multiple dose escalation phase I study in healthy volunteers aiming to evaluate the pharmacokinetic […]

December 5, 2022 - 5 minutesmins - By Jim Cornall

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Inflammatory disease

10 immunotherapy companies making waves in 2023

Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor

Positive topline data from sepsis trial

Certa scleroderma study shows improvement in more than 60% of patients

FDA clearance for ‘revolutionary’ approach to J-Pouch issue

Lupus treatment hope from Japanese miRNA research

CytoReason expands deal with Sanofi to look at IBD

Anticancer drugs could lead to new sepsis treatment

Positive Dupixent eosinophilic esophagitis phase 3 results

Apogee Therapeutics raises $169M to tackle immunological and inflammatory disorders

Tetra announce significant results from the study of Onternabez combined with Favipiravir

First subject dosed in inflammation phase I study

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!